Replies to post #859 on Revance Therapeutics Inc (RVNC)

[iwfal]

yeah to say browne would dilute an ANY cost is a bit extreme - i mean sure he would get new options at the lower price but he has hundreds of thousands of options that would be diluted - and for what one more raise until revenue comes in and the company can fund itself. That decidedly wouldn't be in his self interest.

Agree that I am employing some hyperbole there - but my point still stands that his interests and those of current shareholders are not necessarily all that well aligned given that he will continue to get large numbers of grants/options (e.g. when approved?). And, further, that he just seems to be focused on long term king of the hill. (?)

When on the cusp of approval you can sell a tiny royalty for good money (ala IMMU). you can take a loan to bridge until revenue comes in (like EOLS).

Possibly - but I think part of our disagreement is about odds of success in the various indications currently being RCT'd. I think CD is 90% chance of efficacy success at 24 weeks and is probably widely viewed as such. The biggest risks are probably related to the AE (ability to swallow, FVC - but hopefully they have learned a lot from botox and their drug appears less likely to spread)? CD isn't the same as PF, which is an indication where, as they acknowledge, a large number of institutions have success even in 'placebo' (PF is something for which I have personal experience - some podiatrists have good advice, some horrendous. If you are running an RCT in PF you need to avoid the former.)